To the full analysis
Buyback calculator for Pacific Biosciences of California
Pacific Biosciences of California stock: key metrics
PACBPacific Biosciences of California had an operating margin of −348.5% and a return on invested capital (ROIC) of −69.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 100.0% | −1,081.4% | −994.8% |
| 2008 | 100.0% | −4,973.3% | −4,856.2% |
| 2009 | 100.0% | −65,237.0% | −64,965.2% |
| 2010 | 100.0% | −8,377.2% | −8,373.1% |
| 2011 | 38.5% | −324.1% | −323.0% |
| 2012 | 3.6% | −363.1% | −363.6% |
| 2013 | 22.8% | −275.2% | −281.4% |
| 2014 | 38.6% | −103.7% | −109.2% |
| 2015 | 57.6% | −31.4% | −34.2% |
| 2016 | 48.7% | −78.5% | −82.0% |
| 2017 | 37.1% | −96.1% | −98.6% |
| 2018 | 31.9% | −128.4% | −130.4% |
| 2019 | 38.0% | −110.6% | −92.6% |
| 2020 | 41.3% | −132.3% | 37.3% |
| 2021 | 45.1% | −161.2% | −138.9% |
| 2022 | 38.2% | −239.4% | −244.9% |
| 2023 | 26.3% | −166.8% | −153.0% |
| 2024 | 24.2% | −308.0% | −201.2% |
| 2025 | 31.7% | −348.5% | −341.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 0.0% | no data | 0.0% |
| 2008 | 46.9% | −32.3% | −38.7% |
| 2009 | 49.5% | −68.8% | −86.8% |
| 2010 | −50.1% | −58.7% | −45.8% |
| 2011 | −57.1% | −35.8% | −50.1% |
| 2012 | −86.4% | −47.5% | −72.8% |
| 2013 | −100.0% | −53.6% | −58.2% |
| 2014 | −100.0% | −48.1% | −53.1% |
| 2015 | −43.1% | −22.8% | −24.2% |
| 2016 | −87.8% | −52.8% | −53.9% |
| 2017 | −100.0% | −62.8% | −64.0% |
| 2018 | −89.9% | −58.7% | −60.2% |
| 2019 | −100.0% | −60.0% | −56.9% |
| 2020 | 8.8% | −42.6% | 7.1% |
| 2021 | −22.9% | −43.7% | −9.0% |
| 2022 | −55.8% | −33.7% | −17.8% |
| 2023 | −43.7% | −30.3% | −17.6% |
| 2024 | −61.2% | −41.8% | −24.6% |
| 2025 | −100.0% | −69.1% | −69.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2016)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.